Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology, discusses how curative, high-cost therapies will impact patient out-of-pocket (OOP) costs and cost sharing.
Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology, discusses how curative, high-cost therapies will impact patient out-of-pocket costs and cost sharing.
TranscriptHow have curative, high-cost therapies impacted patient out-of-pocket costs and cost sharing?
Well, for most of these conditions, patients already have very high out-of-pocket costs. We’ve moved, in this country, to a lot of high-deductible plans and have high maximum out of pockets. So, most of these patients, I believe, will already meet their out-of-pocket maximum. So, whether they have an expensive treatment over time or they have one very high-cost treatment, I’m not sure it’s going to make a difference for the member in that year of treatment.
I think the real question is how does this sort of net out for them over time, is one piece, and whether their costs will be less in future years than it would have been if they were having other treatment or they had chronic costs. Or you know, the other question is, just the affordability in general. So, if patients choose not to get this new therapy because they just look at the overall cost and say it’s too much and they forgo therapy all together, that won’t be a good thing either. So, I think it’s a piece that has to be addressed, but it’s a broader issue than just the gene therapies.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More